Lonza is a provider of integrated healthcare solutions. It offers services and products spanning early phase discovery, custom development and manufacturing of active pharmaceutical ingredients, and innovative dosage forms for the pharma and consumer health and nutrition industries. The company focuses on providing treatments that prevent illnesses and support healthier lifestyles. Lonza’s business segments are Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients. The Biologics segment is a contract development and manufacturing partner for biopharmaceuticals, serving customers for all clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug manufacturing. The modalities in Biologics include mammalian and microbial expression systems, bioconjugates, and mRNA. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene segment focuses on Cell and Gene Technologies and Bioscience businesses. The Capsules and Health Ingredients segment specialises in innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies.
The company’s Drug Product Services (DPS) focuses on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Its services include options for monoclonal antibodies, other biologics such as novel formats, noncytotoxic bioconjugates, peptides, viral vectors, and small molecules that require a parenteral dosage form.